GlassScriptPhysician profile
Martin C Penetar
NPI 1366422230
$21,561.81
in general payments reported to CMS, 2019-2025
56 companies · $3,430 in 2025
The $3,430 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,477 · 2020: $2,558 · 2021: $2,636 · 2022: $2,905 · 2023: $3,300 · 2024: $3,255 · 2025: $3,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,985.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,887.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,588.08 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $1,923.81 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,856.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $1,506.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,037.01 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,035.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $900.26 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Daiichi Sankyo INC. | $701.46 | 2019-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $673.56 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $626.82 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $497.13 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Esperion Therapeutics, INC. | $491.51 | 2020-2025 | Nexletol |
| Abbott Laboratories | $366.75 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $350.76 | 2019-2023 | Xarelto |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Penetar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.